Table 3.

Sub-group analysis^a

Sub-group	Non-SSRI users	SSRI users	Deaths, non-SSRI users	Deaths, SSRI users	Hazard ratio (95% CI)	p
Age <39 y	143,316	2246	13	1	4.1 [0.5–31.3]	0.17
Age ≥39 y	136,018	4867	2859	254	1.3 [1.2–1.5]	<0.001
Females	140,209	4703	1279	144	1.3 [1,1–1.6]	<0.001
Males	139,125	2410	1593	111	1.3 [1.1–1.6]	<0.001
Unvaccinated	252,297	6366	2642	234	1.3 [1.2–1.5]	<0.001
Vaccinated	27,037	747	230	21	1.4 [0.9–2.1]	0.18
Charlson Comorbidity Index score = 0	258,086	5858	1112	84	1.6 [1.3–2.0]	<0.001
Charlson Comorbidity Index score = 1–2	17,976	1006	1108	107	1.2 [1.0–1.5]	0.04
Charlson Comorbidity Index score ≥3	3272	249	652	64	1.2 [0.9–1.5]	0.25

SSRI, selective serotonin reuptake inhibitor.

^aDifferences in outcome between SSRI users and non-SSRI users within 60 days after a positive SARS-CoV-2 PCR test for different sub-groups of the study population. The age cut-off was set at 39 years, since 39 was the overall median. Hazard ratios were adjusted for age, sex, vaccination status, and Charlson Comorbidity Index score. See the method section for definitions of individual variables.